Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: 400 mg lyophilized powder ) |
| Drug Class | Zaire ebolavirus glycoprotein directed human monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Summary
- Ansuvimab (Ebanga) is used for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
- A systematic review/meta-analysis consisting of one document was reviewed which provided information on Ebanga's efficacy and safety profile compared to other Ebola virus disease (EVD) treatments.
- The study found that among the most commonly used drugs for EVD - ZMapp, Inmazeb, and Ebanga - ansuvimab (Ebanga) showed a mortality rate of 35.1% when administered as a single intravenous dose at 50mg/kg.
- Compared with Inmazeb which reduced the mortality rate by 17%, ansuvimab (Ebanga)'s higher mortality rate suggests it may be less effective than some alternatives in treating EVD.
- However, according to this analysis, ansuvimab (Ebanga) could be considered as an alternative choice in patients with cardiovascular complications where use of other drugs might not be suitable or safe.
- Common adverse effects observed during treatment with ansuvimab (Ebanga), include fever, tachycardia, diarrhoea, vomiting, hypotension, tachypnea, and chills.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ebanga (ansuvimab-zykl) Prescribing Information. | 2021 | Ridgeback Biotherapeutics, LP, Miami, FL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. | 2022 | Journal of Infection and Public Health |